# Septal reduction therapy (myectomy, alcohol septal ablation)

Intervention · id `cardio:septal-reduction-therapy-myectomy-alcohol-septal-ablation` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Septal myectomy; Alcohol septal ablation; SRT

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Septal reduction therapy (SRT) is the term a 2022 systematic review uses for surgical septal myectomy and alcohol septal ablation, which it calls the two most common forms. The review says SRT is indicated in patients who are refractory to medical treatments and that alcohol septal ablation works by inducing an iatrogenic myocardial infarction. MeSH describes septal myectomy as an open heart surgery to treat hypertrophic cardiomyopathy. The US label of dehydrated alcohol injection (ABLYSINOL) states an indication to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The same review pools 20 studies and reports more ventricular arrhythmia events with alcohol septal ablation than with myectomy; these were cohorts, and the page does not say which procedure is better.

## Technical summary

MeSH descriptor D000099303 (Septal Myectomy) is a broad match: its scope note names only the surgery, so it is narrower than the page, which also covers alcohol septal ablation. Evidence in this atlas: PMC11270481 (Reviews in Cardiovascular Medicine, 2022; CC BY 4.0; introduction and abstract quoted) and the openFDA drug label record for dehydrated alcohol injection, set id 314b1dab-8f4f-49ae-a105-f974842818b8 (NDA207987, BPI Labs, effective 2026-01-05), read for its indication statement only. The openFDA brand name field reads Dehydrated Alcohol while the label text names ABLYSINOL. No dose, technique, outcome registry or guideline was read.

## Claims, with the population each applies to

## Context: Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the US label of dehydrated alcohol injection (ABLYSINOL) states

Recipient: Adult; Population: Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the indication statement words it. The statement gives no age bounds.; Care setting: Not stated beyond the indication statement; Geography: United States (FDA-approved labeling, NDA207987); Life stage: Adults (the label's word); no age bounds given; Follow-up: Not applicable (regulatory statement)

### The openFDA drug label record for dehydrated alcohol injection (ABLYSINOL, BPI Labs, NDA207987; label effective 5 January 2026) states its indication: to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The record's brand name field reads Dehydrated Alcohol, and the label text names ABLYSINOL.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the indication statement words it. The statement gives no age bounds.; Care setting: Not stated beyond the indication statement; Geography: United States (FDA-approved labeling, NDA207987); Life stage: Adults (the label's word); no age bounds given; Follow-up: Not applicable (regulatory statement)
- Limitations: This claim covers one label (set id 314b1dab-8f4f-49ae-a105-f974842818b8). A search of openFDA labels for the word septal in the indications listed ten records, all for dehydrated alcohol with the same indication wording; the other nine were not read. Only the indication statement is recorded; no dosing, administration, warning or clinical study text is recorded on this page. An FDA approval is a decision about a drug, not a finding about how well it works. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987) (Label, edition openFDA drug label record, label effective 20260105, dataset last updated 2026-11-18. The record's brand name field reads Dehydrated Alcohol; the label text names ABLYSINOL.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T17:26:02Z. Source state: Current. Version fingerprint: a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461.
     How it applies: Quoted at this locator.
  2. Supports: openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987) (Label, edition openFDA drug label record, label effective 20260105, dataset last updated 2026-11-18. The record's brand name field reads Dehydrated Alcohol; the label text names ABLYSINOL.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8>
     Locator: results\[0\].openfda.brand\_name\[0\]. Retrieved 2026-11-18T17:26:02Z. Source state: Current. Version fingerprint: a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461.
     How it applies: Quoted at this locator.
  3. Supports: openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987) (Label, edition openFDA drug label record, label effective 20260105, dataset last updated 2026-11-18. The record's brand name field reads Dehydrated Alcohol; the label text names ABLYSINOL.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8>
     Locator: results\[0\].openfda.manufacturer\_name\[0\]. Retrieved 2026-11-18T17:26:02Z. Source state: Current. Version fingerprint: a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461.
     How it applies: Quoted at this locator.
  4. Supports: openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987) (Label, edition openFDA drug label record, label effective 20260105, dataset last updated 2026-11-18. The record's brand name field reads Dehydrated Alcohol; the label text names ABLYSINOL.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:26:02Z. Source state: Current. Version fingerprint: a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461.
     How it applies: Quoted at this locator.
  5. Supports: openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987) (Label, edition openFDA drug label record, label effective 20260105, dataset last updated 2026-11-18. The record's brand name field reads Dehydrated Alcohol; the label text names ABLYSINOL.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8>
     Locator: results\[0\].indications\_and\_usage\[0\], fragment 1 of 2. Retrieved 2026-11-18T17:26:02Z. Source state: Current. Version fingerprint: a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461.
     How it applies: Quoted at this locator.
  6. Supports: openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987) (Label, edition openFDA drug label record, label effective 20260105, dataset last updated 2026-11-18. The record's brand name field reads Dehydrated Alcohol; the label text names ABLYSINOL.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8>
     Locator: results\[0\].indications\_and\_usage\[0\], fragment 2 of 2. Retrieved 2026-11-18T17:26:02Z. Source state: Current. Version fingerprint: a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461.
     How it applies: Quoted at this locator.

## Context: People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them

Recipient: Recipient not specified; Population: Patients with hypertrophic obstructive cardiomyopathy (the review abbreviates it HOCM) who had septal myectomy or alcohol septal ablation in 20 pooled studies. The abstract describes the condition as medical refractory; the pooled studies' own inclusion criteria were not read.; Care setting: Not stated; the pooled studies' settings were not read; Geography: Not stated in the passages read; Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: The abstract reports an early phase (during the procedure, during hospitalization or within 30 days after) and a late phase; no other follow-up period was read

### The same review pooled 20 studies with 8025 patients. Its abstract reports that ventricular tachycardia or ventricular fibrillation, including appropriate implantable cardioverter defibrillator intervention, was significantly more frequent in the alcohol septal ablation cohort than in the septal myectomy cohort (10% against 5%). It says the risks of sudden cardiac death were similar in the two procedure groups, but that a higher incidence of sudden cardiac arrest, which included sudden cardiac death and resuscitated sudden cardiac arrest, was observed in the alcohol septal ablation group.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with hypertrophic obstructive cardiomyopathy (the review abbreviates it HOCM) who had septal myectomy or alcohol septal ablation in 20 pooled studies. The abstract describes the condition as medical refractory; the pooled studies' own inclusion criteria were not read.; Care setting: Not stated; the pooled studies' settings were not read; Geography: Not stated in the passages read; Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: The abstract reports an early phase (during the procedure, during hospitalization or within 30 days after) and a late phase; no other follow-up period was read
- Limitations: The pooled studies are cohorts: the introduction says no randomized controlled study compares the two procedures, so the groups may differ in ways the pooling does not remove. The abstract is the authors' summary; the risk ratios, confidence intervals and study-level data were not reproduced or checked here. The review searched to October 2020. The review does not separate the effect of patient selection from the procedure. This is not advice on which procedure to choose.
- Last checked: 2026-11-18
- Sources:
  1. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Results, sentence 1. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  2. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Results, sentence 2, fragment 1 of 2. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  3. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Results, sentence 2, fragment 2 of 2. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  4. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Results, sentence 2, comparison. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  5. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Results, sentence 5, fragment 1. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  6. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Results, sentence 5, fragment 2. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  7. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Abstract, Conclusions, sentence 1. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.

### The introduction of a 2022 systematic review of ventricular arrhythmias after septal reduction therapy (SRT) says that SRT is indicated in patients who are refractory to medical treatments, and that surgical septal myectomy and alcohol septal ablation are the two most common forms. It says no randomized controlled study compares the two, and that alcohol septal ablation works by inducing an iatrogenic myocardial infarction, unlike the direct resection of the thickened muscle in myectomy.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with hypertrophic obstructive cardiomyopathy (the review abbreviates it HOCM) who had septal myectomy or alcohol septal ablation in 20 pooled studies. The abstract describes the condition as medical refractory; the pooled studies' own inclusion criteria were not read.; Care setting: Not stated; the pooled studies' settings were not read; Geography: Not stated in the passages read; Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: The abstract reports an early phase (during the procedure, during hospitalization or within 30 days after) and a late phase; no other follow-up period was read
- Limitations: Background statements written by the review's authors in its introduction, not the review's results. The review searched to October 2020 and was published in 2022; later evidence, guidelines and the effect of newer medicines were not read. The word indicated is the authors'; no guideline was read for this page.
- Last checked: 2026-11-18
- Sources:
  1. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Introduction, paragraph 1, sentence 4. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  2. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Introduction, paragraph 1, sentence 5. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  3. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Introduction, paragraph 1, sentence 6. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.
  4. Supports: The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Systematic review published 30 November 2022 in the December 2022 issue. Only the abstract and the introduction are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC11270481/>
     Locator: Introduction, paragraph 1, sentence 7. Retrieved 2026-11-18T17:28:57Z. Source state: Current. Version fingerprint: c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559.
     How it applies: Quoted at this locator.

## Connected pages

- The US label of dehydrated alcohol injection states an indication in obstructive hypertrophic cardiomyopathy: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-fda-dehydrated-alcohol-label-indication` and its context]
- A 2022 systematic review describes septal reduction therapy in obstructive hypertrophic cardiomyopathy: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-pmc-srt-two-forms` and its context]
- The same review pools ventricular arrhythmia events after alcohol septal ablation and septal myectomy: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-pmc-srt-arrhythmia-meta-analysis` and its context]
- A medicine for hypertrophic cardiomyopathy is described on its own page: Mavacamten (`cardio:mavacamten`)
- Filed under this front: Procedures and surgery (`cardio:front-procedures-and-surgery`)

## Provenance

Content hash: 1608e97414f27b4f3caf43d80a2aadec25ea8ad14316559459dcb7463aa79d74
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
